Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634480 | 0.98 | GNAI3 (0.57) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL23471206 | 0.98 | GNAI3 (0.57) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL793883 | 0.93 | GNAI3 (0.45) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL25135123 | 0.93 | GNAI3 (0.45) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL19634476 | 0.90 | GNAI3 (0.44) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL19865645 | 0.89 | GNAI3 (0.57) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL23471324 | 0.88 | GNAI3 (0.47) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL21016223 | 0.88 | GNAI3 (0.47) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL19634651 | 0.88 | GNAI3 (0.41) | GNAI3GNAO1GNAI1HTR1ALTA4H | |
| SCHEMBL20231217 | 0.86 | HSD11B1 (0.41) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| EP-0154669-A1 | Catalyst for urethane foam blown with carboxylic acids | ABBOTT LABORATORIES (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0144573-A2 | Catalyst system for the production of polyurethanes | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
| US-4500654-A | N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1985-02-19 | — | — | US | disclosed |
| US-4473666-A | A DIALKYLCYCLOHEXYLAMINE AND AN N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | GNAI3 1569/4885GNAO1 2200/4885GNAI1 1027/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | GNAI3 1569/4885GNAO1 2200/4885GNAI1 1027/4885 |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | GNAI3 2852/4885GNAO1 4461/4885GNAI1 2584/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | GNAI3 1569/4885GNAO1 2200/4885GNAI1 1027/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | GNAI3 849/4885GNAO1 1337/4885GNAI1 704/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | GNAI3 849/4885GNAO1 1337/4885GNAI1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.